The European Commission and national competition authorities imposed fines exceeding €780m ($846m) in relation to 26 cases of pharmaceutical product anti-competitive practices between 2018 and 2022, a new report from the commission has revealed.
These sanctions were made for a variety of reasons, including the misuse of the EU drug patent system to prolong...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?